VolitionRx
Update in progressVNRX (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
VolitionRx Limited is a multinational epigenetics company developing blood tests to detect and monitor cancers and NETosis-related diseases. Operating in the United States, Europe, and Asia, it offers Nu.Q Vet for cancer screening in dogs and other animals; Nu.Q Nets for NETosis-related conditions such as sepsis; Nu.Q Discover for nucleosome profiling; Nu.Q Cancer to predict and monitor treatment response and disease progression; and Capture-PCR/Capture-Seq to isolate circulating tumor DNA from plasma for early detection. Based in Henderson, Nevada.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section